Jazz Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

17.08.17	Jazz Pharmaceuticals Announces Offering of $500 Million of Exchangeable Senior Notes due 2024 (PR Newswire)
11.08.17	Technical Snapshots for These Biotech Stocks -- ImmunoGen, Incyte, Infinity Pharma, and Jazz Pharma (PR Newswire)
08.08.17	Jazz Pharmaceuticals Announces Second Quarter 2017 Financial Results (PR Newswire)
08.08.17	Jazz Pharmaceuticals Announces Second Quarter 2017 Financial Results (PR Newswire)
04.08.17	DVAX Plunges On Delay In Approval, FDA Nod For ABBV's HCV Drug, ABIO On Radar (RTTNews)
04.08.17	FDA Oks Treatment For Certain Types Of Poor-prognosis Acute Myeloid Leukemia (RTTNews)
03.08.17	Jazz Pharmaceuticals Announces Webcast for Vyxeos Investor Update (PR Newswire)
31.07.17	PDL BioPharma to Announce Second Quarter 2017 Financial Results on August 3, 2017 (PR Newswire)
26.07.17	Jazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation® Technology to Develop Long-Acting Asparaginase Product Candidates (PR Newswire)
26.07.17	Jazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation® Technology to Develop Long-Acting Asparaginase Product Candidates (PR Newswire)
24.07.17	Jazz Pharmaceuticals to Report 2017 Second Quarter Financial Results on August 8, 2017 (PR Newswire)
24.07.17	Jazz Pharmaceuticals to Report 2017 Second Quarter Financial Results on August 8, 2017 (PR Newswire)
06.06.17	Jazz Pharmaceuticals Presents JZP-110 Data in Patients with Excessive Sleepiness Associated with Obstructive Sleep Apnea (PR Newswire)
06.06.17	Jazz Pharmaceuticals Presents JZP-110 Data in Patients with Excessive Sleepiness Associated with Obstructive Sleep Apnea (PR Newswire)
06.06.17	Jazz Pharmaceuticals Presents Data for the Phase 3 TONES 2 Study of JZP-110 in Patients with Excessive Sleepiness Associated with Narcolepsy (PR Newswire)
01.06.17	FDA Greenlights Novo Nordisk's Rebinyn, TEVA's HALO Shines, LUCY Walks The Talk (RTTNews)
31.05.17	Jazz Pharmaceuticals Announces FDA Acceptance of NDA for VYXEOS™ (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia, with Priority Review Status (PR Newswire)
31.05.17	Jazz Pharmaceuticals Announces FDA Acceptance of NDA for VYXEOS™ (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia, with Priority Review Status (PR Newswire)
31.05.17	Research Reports Initiation on Biotech Stocks -- Kite Pharma, Arrowhead Pharma, Ultragenyx Pharma, and Jazz Pharma (PR Newswire)
24.05.17	Jazz Pharmaceuticals Announces Webcast Discussion of Data to be Presented at APSS (PR Newswire)
24.05.17	Jazz Pharmaceuticals Announces Webcast Discussion of Data to be Presented at APSS (PR Newswire)
24.05.17	Jazz Pharmaceuticals to Present Phase 3 Data on JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy and with Obstructive Sleep Apnea, During 31st Annual SLEEP... (PR Newswire)
24.05.17	Jazz Pharmaceuticals to Present Phase 3 Data on JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy and with Obstructive Sleep Apnea, During 31st Annual SLEEP... (PR Newswire)
16.05.17	Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences (PR Newswire)
09.05.17	Jazz Pharmaceuticals Announces First Quarter 2017 Financial Results (PR Newswire)
09.05.17	Jazz Pharmaceuticals Announces First Quarter 2017 Financial Results (PR Newswire)
26.04.17	Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 2 Study of JZP-110 in Narcolepsy Patients with Excessive Sleepiness (PR Newswire)
25.04.17	Jazz Pharmaceuticals to Report 2017 First Quarter Financial Results on May 9, 2017 (PR Newswire)
25.04.17	Jazz Pharmaceuticals to Report 2017 First Quarter Financial Results on May 9, 2017 (PR Newswire)
25.04.17	D-Day For CAPR Today, OMED Hands Out Pink Slips, JAZZ Hits Right Notes... (RTTNews)
24.04.17	Jazz Pharmaceuticals Announces Positive Results from the Phase 2/3 EXPRESS Study of Xyrem in Pediatric Patients with Narcolepsy with Cataplexy (PR Newswire)
24.04.17	Jazz Pharmaceuticals Announces Positive Results from the Phase 2/3 EXPRESS Study of Xyrem in Pediatric Patients with Narcolepsy with Cataplexy (PR Newswire)
06.04.17	ARLZ Hands Out Pink Slips, JAZZ On A High Note, STDY On Track, TENX Abuzz (RTTNews)
05.04.17	Jazz Pharmaceuticals Reaches Settlement with Hikma Pharmaceuticals Related to Xyrem Patent Litigation (PR Newswire)
05.04.17	Jazz Pharmaceuticals Reaches Settlement with Hikma Pharmaceuticals Related to Xyrem Patent Litigation (PR Newswire)
03.04.17	Jazz Pharmaceuticals Completes Rolling Submission of New Drug Application for Vyxeos™ (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia (PR Newswire)
03.04.17	Jazz Pharmaceuticals Completes Rolling Submission of New Drug Application for Vyxeos™ (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia (PR Newswire)
30.03.17	Jazz Pharmaceuticals and Nippon Shinyaku Enter Into License Agreements for the Development and Commercialization of Defitelio and Vyxeos in Japan (PR Newswire)
30.03.17	Jazz Pharmaceuticals and Nippon Shinyaku Enter Into License Agreements for the Development and Commercialization of Defitelio and Vyxeos in Japan (PR Newswire)
21.03.17	PTIE Surges After-hours, Valeant Gets FDA Date, JAZZ Hits Right Notes (RTTNews)
20.03.17	Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 3 and TONES 4 Studies of JZP-110 in Patients with Obstructive Sleep Apnea (PR Newswire)
20.03.17	Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 3 and TONES 4 Studies of JZP-110 in Patients with Obstructive Sleep Apnea (PR Newswire)
15.03.17	Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Study Evaluating JZP-258 for the Treatment of Cataplexy and Excessive Daytime Sleepiness in Narcolepsy (PR Newswire)
15.03.17	Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Study Evaluating JZP-258 for the Treatment of Cataplexy and Excessive Daytime Sleepiness in Narcolepsy (PR Newswire)
01.03.17	Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March (PR Newswire)
01.03.17	Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March (PR Newswire)
28.02.17	Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2016 Financial Results (PR Newswire)
28.02.17	Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2016 Financial Results (PR Newswire)
14.02.17	Jazz Pharmaceuticals to Report 2016 Fourth Quarter and Full Year Financial Results on February 28, 2017 (PR Newswire)
14.02.17	Jazz Pharmaceuticals to Report 2016 Fourth Quarter and Full Year Financial Results on February 28, 2017 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Novartis	98.58	3.13 %	K V
Roche Hldg G	291.30	1.85 %	K V
Sonova Hldg	309.00	1.25 %	K V
Part Grp Hldg	1’395.50	1.23 %	K V
Alcon	83.82	1.23 %	K V
Givaudan	3’917.00	0.13 %	K V
Nestle	77.26	-0.26 %	K V
Sika	227.10	-0.48 %	K V
ABB	49.03	-0.65 %	K V
UBS Group	29.10	-1.52 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Jazz Pharmaceuticals PLC

Aktien Top/Flop

Meistgelesene Nachrichten